Harvard Business Review

JUNE 7, 2012

PwC's Health Research Institute projects medical costs will increase 7.5% for 2013, the fourth year in a row of relatively flat growth. PwC says four forces will continue to slow the rise in medical cost trend in 2013: 1. Pharmaceutical patent expirations are increasing the use of cheaper generic drugs.

Disruptive Innovation 22

Disruptive Innovation Innovation Pharmaceuticals Class 22

Harvard Business Review

JUNE 7, 2012

PwC's Health Research Institute projects medical costs will increase 7.5% for 2013, the fourth year in a row of relatively flat growth. PwC says four forces will continue to slow the rise in medical cost trend in 2013: 1. Pharmaceutical patent expirations are increasing the use of cheaper generic drugs.

Disruptive Innovation 12

Disruptive Innovation Innovation Pharmaceuticals Class 12

Harvard Business Review

OCTOBER 24, 2013

Among the effects: 703 fewer new and competing research projects. noted the irony that because of sequester cuts, NIH funding was reduced for the research that resulted in Yale’s James Rothman sharing in the 2013 Nobel Prize for Medicine. Cuts to 2013 budget : $285 Million or 5%. Cuts to 2013 budget: $11.08

Health Care 8

Health Care Budgeting Pharmaceuticals Review 8

Harvard Business Review

OCTOBER 27, 2014

doubled from 20% to 40% between July and December 2013, and has stayed at that level since. I studied large-scale change and innovation efforts in 56 randomly selected companies in the high-tech, retail, pharmaceutical, banking, automotive, insurance, energy, non-profit, and health care industries. Change leaders are visionaries.

Middle Management 13

Middle Management Six Sigma Taylorism Taylor 13

Harvard Business Review

FEBRUARY 6, 2014

Consider the CEO succession process at pharmaceutical giant GlaxoSmithKline beginning in 2004 when chief executive Jean-Pierre Garnier said he would be exiting in three years. Or consider managed-health care provider Humana’s decision in 2013 to recruit an outsider as its next chief executive.

CEO 8

CEO Bottom-up Strategic Fit Pharmaceuticals 8

Harvard Business Review

FEBRUARY 11, 2016

In this excerpt from their book, Agile Talent , Younger and Smallwood explain how to align your organization with the needs and expectations of a workforce that is increasingly external, project-based, and flexible. Studies of the global agile-talent community vary in their estimates of the size of the population.

Agility 8

Agility Organization Resources Fixed Costs 8

Harvard Business Review

MAY 5, 2016

sanctions are delaying these projects being financed. However, oil prices have dropped more than 60% since the interim nuclear deal in November 2013. And Danish pharmaceutical company Novo Nordisk is building on its Iran presence by doubling local staff to nearly 300 and investing $76 million in a new factory.

Tourism 8

Tourism Banking Due Diligence Hotels 8